My point here is that 434 could well have a positive effect on the atrophy progression of gray matter, and not only basal ganglion atrophy as was reported by Claassen. In the 202 study, the best effect was seen with 50mg in the USARS (48% better than the placebo). It is perhaps a little easier to think that the UMSARS components could relate better with gray matter atrophy ( see the paper above: balance, gait, etc) than basal ganglion atrophy (??). So 434 could have a positive effect also in the gray matter, but today we do not know if that was the case.
From the point of AD, this would be wonderful information to know.
My point here is that 434 could well have a positive effect on...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $100.4M | |||
| Open | High | Low | Value | Volume |
| 1.0¢ | 1.1¢ | 1.0¢ | $60.81K | 5.737M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 37 | 16255465 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.1¢ | 1643984 | 2 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| ATH (ASX) Chart |